8-K current report · filed Oct 15, 2026

Krystal Biotech, Inc. (KRYS) 8-K Current Report: October 15, 2026

Item 7.01KRYS overview

Short answer

Krystal Biotech, Inc. (KRYS) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). KB113 Gorlin Syndrome pilot data announced for basal cell carcinoma treatment.

Krystal Biotech, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • KB113 Gorlin Syndrome pilot data announced for basal cell carcinoma treatment
  • Clinical results presented at PeDRA Annual Conference, October 15–17, 2026
  • Poster and press release available as Exhibits 99.1 and 99.2
  • Data may inform KB113’s development potential in a rare, genetically driven skin-cancer population

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Krystal Biotech, Inc. 8-K filings

Get the next KRYS 8-K as it lands

Follow KRYS for push alerts, or ask the research agent what this filing means.